July 24
ABU DHABI, UAE, July 24, 2011 -
- The Investment Will Almost Double
EMAL's Production Capacity to 1.3 Million Tonnes
Emirates Aluminium (EMAL) has announced that Phase II of its
operational plan will go ahead after the company's board of
directors approved a $4.5bn investment, based on the success in
reaching full production of the smelter's Phase I.
DUBAI, UAE, July 24, 2011 -
Middle East'sLargest Daily Deal Site Reaches600,000Subscribers
SiteSpread Across Five CountriesandNine Cities After Nine MonthsofOperation
Daily deal web siteCobone.comhas raised an undisclosed amount of second-round funding from Jabbar Internet Group.
DUBAI, UAE, July 24, 2011 -
The renewable energy sector could drive economic development in Africa and could possibly compete internationally in future, London-based merchant bank NextEnergy Capital CEO Stefano Sommadossi told Engineering News Online
Renewable energy companies and developers in Africa are struggling to get their projects off the ground because they don't have the right financial backing.
WASHINGTON, July 24, 2010 - Today, the U.S.
BASEL, Switzerland -
- Not For US Media
- Set to Become First Medicine in EU to Treat Patients Aged Four and Older Suffering From Life-Long Cryopyrin-Associated Periodic Syndrome (CAPS)(1)
- Ilaris Targets Interleukin-1 Beta (IL-1 Beta), a key Driver of Inflammation(1,2,3) - Studies Ongoing in Other Diseases Involving IL-1 Beta Such as Gout, COPD and Type 2 Diabetes
- EU Opinion Follows US and Swiss Approvals Based on Data Showing Ilaris Produced Rapid and Sustained Remission in CAPS Patients After one Dose(2)
- CAPS Comprises Three Disorders of Increasing Severity With Potentially Fatal Complications(2,3) - Most Patients Suffer From Severe and Disabling Symptoms(1,3)
The biotechnology medicine Ilaris(R) (canakinumab) has passed another major milestone with a recommendation for approval in the European Union to treat patients with a life-long and potentially fatal auto-inflammatory disease called cryopyrin-associated periodic syndrome (CAPS).
